Loading...
EVROF logo

Evrofarma SAATSE:EVROF Stock Report

Market Cap €49.8m
Share Price
n/a
1Y43.9%
7D-1.1%
1D3.1%
Portfolio Value
​
View

Evrofarma SA

ATSE:EVROF Stock Report

Market Cap: €49.8m

Evrofarma (EVROF) Stock Overview

Produces and sells dairy products in Greece. More details

EVROF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health4/6
Dividends1/6

Rewards

Price-To-Earnings ratio (14.1x) is below the Food industry average (16.1x)

Earnings grew by 54.6% over the past year

Risk Analysis

Has a high level of debt

Does not have a meaningful market cap (€50M)


EVROF Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW486,260 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
486,260 investors already sharing narratives
View all narratives

Evrofarma SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evrofarma
Historical stock prices
Current Share Price€3.64
52 Week High€4.07
52 Week Low€2.38
Beta0.71
1 Month Change-6.91%
3 Month Change0.83%
1 Year Change43.87%
3 Year Change237.04%
5 Year Change230.91%
Change since IPO-30.24%

Recent News & Updates

Analysis Article • Dec 24

Returns On Capital Are Showing Encouraging Signs At Evrofarma (ATH:EVROF)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Recent updates

Analysis Article • Dec 24

Returns On Capital Are Showing Encouraging Signs At Evrofarma (ATH:EVROF)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
Analysis Article • Jul 30

Optimistic Investors Push Evrofarma SA (ATH:EVROF) Shares Up 32% But Growth Is Lacking

Evrofarma SA ( ATH:EVROF ) shares have continued their recent momentum with a 32% gain in the last month alone. Looking...
Analysis Article • May 31

Risks To Shareholder Returns Are Elevated At These Prices For Evrofarma SA (ATH:EVROF)

With a median price-to-earnings (or "P/E") ratio of close to 13x in Greece, you could be forgiven for feeling...
Analysis Article • Dec 19

A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

It's not a stretch to say that Evrofarma SA's ( ATH:EVROF ) price-to-earnings (or "P/E") ratio of 10.2x right now seems...
Analysis Article • Oct 02

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Despite Evrofarma SA's ( ATH:EVROF ) recent earnings report having lackluster headline numbers, the market responded...
Analysis Article • Feb 29

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA ( ATH:EVROF ) shares have continued their recent momentum with a 30% gain in the last month alone. The...
Analysis Article • Jan 06

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Despite an already strong run, Evrofarma SA ( ATH:EVROF ) shares have been powering on, with a gain of 33% in the last...
Analysis Article • Jan 05

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Analysis Article • Dec 01

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Sep 15

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...
Analysis Article • May 27

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Oct 04

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Evrofarma SA's ( ATH:EVROF ) robust earnings report didn't manage to move the market for its stock. We did some...
Analysis Article • May 19

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

When researching a stock for investment, what can tell us that the company is in decline? When we see a declining...
Analysis Article • Feb 22

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Analysis Article • Dec 29

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Analysis Article • Nov 22

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Shareholder Returns

EVROFGR FoodGR Market
7D-1.1%-0.7%1.4%
1Y43.9%4.9%19.2%

Return vs Industry: EVROF exceeded the Greek Food industry which returned 4.9% over the past year.

Return vs Market: EVROF exceeded the Greek Market which returned 19.2% over the past year.

Price Volatility

Is EVROF's price volatile compared to industry and market?
EVROF volatility
EVROF Average Weekly Movement3.5%
Food Industry Average Movement4.4%
Market Average Movement4.0%
10% most volatile stocks in GR Market6.3%
10% least volatile stocks in GR Market2.5%

Stable Share Price: EVROF has not had significant price volatility in the past 3 months compared to the Greek market.

Volatility Over Time: EVROF's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991178Paschalis Papazilakiswww.evrofarma.gr

Evrofarma SA produces and sells dairy products in Greece. The company sells milk, yogurt, feta cheese, and cheese products, as well as fermented beverages. The company also exports its products.

Evrofarma SA Fundamentals Summary

How do Evrofarma's earnings and revenue compare to its market cap?
EVROF fundamental statistics
Market cap€49.76m
Earnings (TTM)€3.53m
Revenue (TTM)€49.44m
14.1x
P/E Ratio
1.0x
P/S Ratio

Is EVROF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVROF income statement (TTM)
Revenue€49.44m
Cost of Revenue€38.92m
Gross Profit€10.52m
Other Expenses€7.00m
Earnings€3.53m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 25, 2026

Earnings per share (EPS)0.26
Gross Margin21.29%
Net Profit Margin7.13%
Debt/Equity Ratio82.0%

How did EVROF perform over the long term?

See historical performance and comparison

Dividends

1.6%
Current Dividend Yield
23%
Payout Ratio

Does EVROF pay a reliable dividends?

See EVROF dividend history and benchmarks
When do you need to buy EVROF by to receive an upcoming dividend?
Evrofarma dividend dates
Ex Dividend DateSep 15 2026
Dividend Pay DateSep 22 2026
Days until Ex dividend50 days
Days until Dividend pay date57 days

Does EVROF pay a reliable dividends?

See EVROF dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/27 05:50
End of Day Share Price 2026/07/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.